Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update, revealing plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. The company stated that CL-741 targets EGFR-mutated lung cancer and other cancers, complementing its existing portfolio that includes ENV-105, KROS-201, KROS-102, and ENV-205.
Looking ahead, Kairos expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations. The company also noted it has secured more than $8 million in non-dilutive funding to support the development of its preclinical and clinical programs. For more details, the full press release is available at https://ibn.fm/WuBOf.
Kairos Pharma, based in Los Angeles, California, is focused on oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The proposed acquisition of CL-741 represents a strategic expansion of Kairos's pipeline into targeted oral therapies, potentially broadening its reach in the oncology market. The company's ability to secure non-dilutive funding underscores investor confidence and provides financial stability for advancing its programs. Investors can find the latest news and updates relating to KAPA in the company’s newsroom at https://ibn.fm/KAPA.
This update comes as Kairos Pharma continues to position itself as a key player in overcoming drug resistance in cancer treatment, with multiple clinical milestones expected in the coming months. The announcement highlights the company's commitment to addressing critical gaps in oncology care through innovative therapies.
